Melanoma is a neoplasm that originates from melanocytes, pigment-producing cells in the skin. Melanoma is a relatively immunogenic tumour, as demonstrated by the presence of both cytotoxic T lymphocytes (CTLs) and antibodies (Mettes et al., 1983; Knuth et al., 1992) in melanoma patients that react with melanoma tumour cells. The availability of antibodies and CTLs with anti-melanoma reactivity allowed the identification of several tumour-associated antigens. These include tumour-specific antigens and melanocyte differentiation antigens that are expressed by melanoma tumour cells as well as by normal melanocytes and retina (van der Bruggen et al., 1991; Bricard et al., 1993; Vijayasaradhi et al., 1990; Bakker et al., 1994; Kawakami et al., 1994a, b; Coulie et al., 1994; Gaugler et al., 1994 and Wang et al., 1995). Identification of the antigens recognised by anti-tumour CTL is important for understanding the molecular basis of tumour recognition by T cells and may lead to the development of new immunotherapeutic strategies to treat cancer patients.

Recently, we cloned the cDNA encoding the melanocyte lineage-specific antigen gp100 and demonstrated that gp100 is recognised by three different monoclonal antibodies (MAbs) used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50 (Adema et al., 1993, 1994). In addition, we demonstrated that gp100 is recognised by a tumour-infiltrating lymphocyte (TIL 1200) from a melanoma patient (Bakker et al., 1994). Molecular characterisation of the cDNA encoding gp100 revealed that it is a type I transmembrane glycoprotein of 641 amino acids highly homologous to another melanocyte-specific protein, pMell17 (Adema et al., 1993, 1994; Kwon et al., 1991). Nucleotide sequence analysis of genomic DNA indicated that the transcripts corresponding to gp100 and pMell17 cDNAs originate from a single gene via alternative splicing. The difference between gp100 and pMell17 consists of a stretch of seven amino acids in the carboxy terminal part of pMell17 (position 367; Adema et al., 1994) that is absent in gp100. In all normal and malignant melanocytic cells expressing the gp100/pMell17 gene, gp100 and pMell17 mRNAs are expressed simultaneously.

Here, we demonstrate that pMell17, like gp100, is recognised by all three MAbs used to diagnose malignant melanoma and is properly processed and presented to anti-melanoma tumour-infiltrating lymphocytes.

Materials and methods
Cells and monoclonal antibodies
Culturing of the melanoma cell lines MEWO, BLM and of COS-7 cells has been described previously (Adema et al., 1993, 1994). TIL 1200 was generated from a metastatic melanoma and cultured with 1000 U ml−1 interleukin-2 (IL-2) (Cetus Corp., Emeryville, CA, USA) as described previously (Kawakami et al., 1992). NKI-beteb and HMB-50 have been described previously (Vennegoor et al., 1988; Vogel and Esclamado, 1988). HMB-45 was purchased from Enzo Biochem.

Molecular cloning and nucleotide sequence analysis
Using a reverse transcriptase-polymerase chain reaction (PCR) (GeneAmp kit, Perkin elmer, the Netherlands) approach with 5'-ctgcatggagatcttcatcg-3' as the 5' primer and 5'-ctcactggtatcccttcatcg-3' as the 3' primer we isolated the 3' part of pMell17 cDNA from total RNA isolated from the melanoma cell line MEWO. The PCR product was used to replace the 3' part of the gp100 cDNA as present in pSVLgp100+ (Adema et al., 1994) using BglII and the newly created SacI site in the 3' primer (underlined). The resulting construct, pSVLpMell17, was sequenced by the dideoxy-nucleotide sequencing method using T7 DNA polymerase (Pharmacia, Woerden, The Netherlands).

Transfections and immunostaining
Transient expression of DNA constructs in COS-7 cells was performed using 40 µg ml−1 lipofectin reagent (BRL, Gaithersburg, MD, USA) and 7.5 µg of DNA. BLM cells were transfected with 20 µg of pCMVneoPmel17 DNA using calcium phosphate transfection systems (BRL, Gaithersburg, MD, USA) and stable clones were isolated by G418 selection (1 mg ml−1) as previously described (Bakker et al., 1994).
Transfected cells were prepared for immunofluorescence using FITC-conjugated GAM-IgG-F(ab')2 (Zymed, San Francisco, CA, USA) as described previously (Adema et al., 1993) and examined using confocal laser scanning microscope at 488 nm (Biorad MRC 600).

Metabolic labelling and immunoprecipitations

Immunoprecipitation experiments were performed on metabolically labelled (L-[35S]methionine/cysteine; Amer sham) cells as described by Vennebroek et al. (1988) using either NK1-beteb or HMB-50 covalently linked to protein A-CN 4B sepharose beads (Pharmacia, Woerden, The Netherlands). Immunoprecipitates were analysed under reducing conditions by SDS-PAGE using 5-17.5% gradient gels. The relative molecular weight of the proteins was determined using co-electrophorised, prestained markers (BRL, Gaithersburg, MD, USA). Gels were treated with 1 M sodium salicylate (pH 5.4) before autoradiography (Kodak XAR).

Chromium-release assay

Chromium release assays were performed as described previously (Bakker et al., 1994). Briefly, 10⁶ target cells were incubated with 100 μCi [32P]sodium chromate (Amer sham, Bucks, UK) for 1 h. Various amounts of effector cells were then added to 2 x 10⁶ target cells in triplicate wells of 24-well microtitre plates (Costar, Badhoevedorp, The Netherlands) in a final volume of 150 µl. After 5 h of incubation part of the supernatant was harvested and its radioactive content was measured.

Results

The gp100/pMel17 gene encodes both gp100 and pMel17 mRNA as a consequence of alternative RNA processing. The pMel17 mRNA encodes a stretch of seven amino acids not encoded by the gp100 mRNA (Figure 1). To investigate the immunological properties of pMel17 we constructed a pMel17 cDNA. Using an RT-PCR approach we first cloned the 3' part of the pMel17 cDNA encoding the carboxy terminal part of pMel17, including the additional seven amino acids absent in gp100. Nucleotide sequence analysis of the 3' part confirmed the presence of the nucleotide sequence

Figure 1 Peptides unique in pMel17 and gp100 that fit the HLA-A2.1 binding motifs [Falk et al. (1991), Drijfhout et al. (1995)]. The pMel17 specific amino acids are indicated in bold.
encoding the pMel17-specific amino acids. In addition, we found pMel17 cDNAs containing either a thymidine (as in the gp100 cDNA; Adema et al., 1994) or a cytosine at position 1998. This nucleotide change does not result in an amino acid substitution. The finding that the same nucleotide difference was found in a gp100 cDNA clone isolated from the same cell line, indicates that this particular cell line contains two different alleles of the gp100/pMel17 gene. Subsequently, we created a full length pMel17 cDNA by exchanging the 3' part of the gp100 cDNA with the 3' part of pMel17 cDNA.

To investigate whether the difference between gp100 and pMel17 affects recognition by the anti-gp100 MAbs NKI-beteb, HMB-45 and HMB-50, we transfected the cDNA encoding pMel17 into the gp100/pMel17 negative melanoma cell line BLM. As shown in Figure 2, expression of the pMel17 cDNA resulted in immunoreactivity with all three MAbs. The typical speckled staining pattern of the pMel17 transfectants was identical to that previously observed for gp100, suggesting that pMel17, like gp100, localises in melanosomes. Immunoreactivity with all three MAbs was also observed when pMel17 cDNA was transiently expressed in non-melanocytic COS-7 cells (data not shown). We also analysed the pMel17 protein detected by MAbs NKI-beteb or HMB-50 in extracts from COS-7 cells transfected with the pMel17 cDNA using immunoprecipitations reactions. As shown in Figure 3, the pMel17 protein is recognised by NKI-beteb and HMB-50 in extracts from pSVLpMel17 transfected COS-7 cells, MEWO cells (MEWO) and COS-7 cells transfected with either pSVLpMel17 (pMel17), pSVLgp100 (gp100) or with a construct encoding the gp100 cDNA in the non-coding orientation (Mock) were metabolically labelled and subjected to immunoprecipitations using NKI-beteb (NKI), HMB-50 (50) or normal mouse serum (NMS) as indicated above each lane. Immunoprecipitated proteins were analysed under reducing conditions by SDS - PAGE (linear gradient of 5 - 17% acrylamide) and visualised by autoradiography. The position and size (kDa) of prestained molecular weight markers are indicated.

Figure 3 The pMel17 protein is recognised by NKI-beteb and HMB-50 in extracts from pSVLpMel17 transfected COS-7 cells, MEWO cells (MEWO) and COS-7 cells transfected with either pSVLpMel17 (pMel17), pSVLgp100 (gp100) or with a construct encoding the gp100 cDNA in the non-coding orientation (Mock). The pMel17 protein co-migrates with the gp100 protein immunoprecipitated from COS-7 cells transfected with gp100 cDNA as well as with the proteins immunoprecipitated from MEWO melanoma cells. The slight difference in mobility between transfected COS-7 cells and MEWO melanoma cells, which express both gp100 and pMel17 endogenously, has previously been shown to be due to differential glycosylation (Adema et al., 1994). To investigate whether the pMel17 antigen also gives rise to peptide epitopes that gain access to the MHC class I antigen presentation pathway, we determined the cytolytic activity of TIL 1200 against HLA-A2.1 + BLM cells transfected with the pMel17 cDNA. As demonstrated in Figure 4, the pMel17 transfectants were efficiently lysed by TIL 1200. No specific lysis was observed using the parental, untransfected BLM cells or BLM cells transfected with the expression vector without an insert (not shown). These data demonstrate that peptide epitope(s) recognised by TIL 1200 are properly processed from the pMel17 protein and presented in the context of HLA-A2.1. Two gp100-derived peptides (corresponding to the amino acids at positions 154 - 162 and 457 - 466) have been identified that are recognised by TIL 1200 (Bakker et al., 1995; Kawakami et al., 1995). These peptides are located in the common part between gp100 and pMel17. Since TIL 1200 is an oligoclonal, CD8+ T-cell line expressing a restricted number of T-cell receptors (Shilyanski et al., 1994), it is most likely that either one or both the aforementioned immunogenic peptides are responsible for the observed lysis of the pMel17 and gp100 transfectants.
The finding that not only gp100 but also it has T-cell line recognised by TIL1200 in the common part of are recognised by TIL. This finding is also from the pMell7 antigen and that are targets for specific immunotherapy. Potentially, these antigens are melanocytes as well as in retina have been identified as targets for anti-melanoma CTLs. Potentially, these antigens are melanocytes as well as in retina have been identified as targets for anti-melanoma CTLs. Potentially, these antigens are targets for immunotherapy.

**Discussion**

The data described in this report demonstrate that pMell17, like gp100, is recognised by three MAbS frequently used to diagnose melanoma. In addition, we demonstrate that cells transfected with pMell17 cDNA are effectively lysed by anti-melanoma T cells.

Because of the exclusive reactivity of MAbS NK1-bet, HMB-45 and HMB-50 with cells of the melanocyte lineage, they are frequently used to diagnose malignant melanoma (Rutier, 1990). The finding that not only gp100 but also pMell7 reacts with these antibodies emphasises the specific expression of both gp100 and pMell7 in cells of the melanocyte lineage. The identical staining pattern observed with the MAbS in gp100 and pMell17 transfecants further indicates that, like gp100, pMell7 is also present in melanomas, which is in line with their proposed role in the process of pigmentation (Kwon et al., 1991). Whether there exists a functional difference between gp100 and pMell7 remains to be determined.

The relative immunogenicity of melanoma tumours has long been recognised. Both cytotoxic T cells and MAbS have been identified that specifically recognise melanoma tumours. So far, a number of the antigens recognised have been characterised in detail. They include the tumour-specific proteins, MAGE-1 (van der Bruggen et al., 1991) and MAGE-3 (Gaugler et al., 1994), which are expressed in different types of tumour cells and in tests. In addition, the melanocyte differentiation antigens tyrosinase, gp100, Melan-A/MART-1 and gp75 (Brichard et al., 1993; Bakker et al., 1994; Kawakami et al., 1994a,b; Coulie et al., 1994; Wang et al., 1995) that are expressed in normal and malignant melanocytes as well as in retina have been identified as targets for anti-melanoma CTLs. Potentially, these antigens are targets for specific immunotherapy.

TIL1200 was isolated from a melanoma metastasis and was shown to recognise the melanocyte differentiation antigen gp100. Interestingly, reinfection of in vitro expanded TIL1200 together with IL-2 in the autologous patient resulted in objective tumour regression (Kawakami et al., 1994b, 1995). Here we demonstrate that TIL1200 not only recognises the gp100 antigen, but also the pMell7 antigen that is encoded by an mRNA species derived from the same gene via alternative splicing. Since we have previously shown that melanoma cells express gp100 and pMell7 mRNA simultaneously, both proteins contribute to the total amount of immunogenic peptides presented in the context of HLA-A2.1 that are recognised by TIL1200. This finding is also consistent with the recent mapping of two peptide epitopes (corresponding to the amino acids at positions, 154-162 and 457-466) recognised by TIL1200 in the common part of gp100 and pMell7 (Bakker et al., 1995; Kawakami et al., 1995 and Figure 5). Although it has been observed that sequence context can affect processing and/or presentation of T-cell epitopes (Eisenlohr et al., 1992; Del Val et al., 1991), this does not seem to be the case for pMell17 and gp100. The fact that TIL1200 is an oligoelonal, CD8+ T-cell line expressing a restricted number of T-cell receptors (Shilyanski et al., 1994), implies that either one or both these epitopes are properly processed from the pMell7 antigen and presented by HLA-A2.1. Attempts to further investigate the recognition of the pMell17 epitopes using cloned TIL have not been successful.

Besides TIL1200, other CTL-recognising distinct epitopes encoded by the gp100/pMell7 have recently been characterised (Cox et al., 1994; Kawakami et al., 1995). A total of five distinct peptides have now been identified (Figure 5), all of which are present in both gp100 and pMell7, and are presented by the same restriction element, HLA-A2.1. Examination of the additional amino acid sequence present

---

**Figure 5** Amino acid sequence of the pMell7 antigen (including signal peptide) and location of the peptide epitopes. The peptide epitopes as recognised in the gp100 antigen are underlined (Bakker et al., 1995), Kawakami et al. (1995), Cox et al. (1994): the amino acids uniquely present in pMell7 are in italic capitals.
in pMel7 revealed that six peptides (including 9- and 10mers) bearing the HLA-A2.1 binding motif are uniquely present in pMel7, whereas three peptides are specifically present in gp100 (Figure 1). HLA-A2.1 stabilisation experiments revealed that two of the pMel7-specific peptides listed in Figure 1 bind to HLA-A2.1 (ABHB and GTVA, unpublished observation). When analysing immunoreactivity against the products of the gp100/pMel7 gene, one should therefore include both gp100 and pMel7.

In conclusion, the data presented in this report demonstrate that pMel7 is recognised by three different Mabs used to diagnose melanoma and functions as a target for anti-melanoma CTLs.

Acknowledgements
We would like to thank Dr Y Kawakami (Surgery Branch, NIH, Bethesda, USA) for providing TIL1200 and Ms M Meijer for secretarial help. This work was supported by the Dutch Cancer Society.

References


